tbuckley/cabot-search huggingface dataset:
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
Authors: Ander Puyalto, María Rodríguez-Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, Anna Vilalta-Lacarra, Connor Welch, Sergio Sandiego, Silvestre Vicent, Karmele Valencia, Alfonso Calvo, Ruben Pio, Luis E. Raez, Christian Rolfo, Daniel Ajona, Ignacio Gil-Bazo
Journal: Molecular Cancer (2024)

Abstract Background The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes the effects of trametinib on Id1 protein, a key factor involved in the KRAS oncogenic pathway, and investigates the role of Id1 in the acquired resistance to trametinib as well as the synergistic anticancer effect of trametinib combined with immunotherapy in KRAS -mutant LUAD. Methods We evaluated the effects of trametinib on KRAS -mutant LUAD by Western blot, RNA-seq and different syngeneic mouse models. Genetic modulation of Id1 expression was performed in KRAS -mutant LUAD cells by lentiviral or retroviral transductions of specific vectors. Cell viability was assessed by cell proliferation and colony formation assays. PD-L1 expression and apoptosis were measured by flow cytometry. The anti-tumor efficacy of the combined treatment with trametinib and PD-1 blockade was investigated in KRAS -mutant LUAD mouse models, and the effects on the tumor immune infiltrate were analyzed by flow cytometry and immunohistochemistry. Results We found that trametinib activates the proteasome-ubiquitin system to downregulate Id1 in KRAS -mutant LUAD tumors. Moreover, we found that Id1 plays a major role in the acquired resistance to trametinib treatment in KRAS -mutant LUAD cells. Using two preclinical syngeneic KRAS -mutant LUAD mouse models, we found that trametinib synergizes with PD-1/PD-L1 blockade to hamper lung cancer progression and increase survival. This anti-tumor activity depended on trametinib-mediated Id1 reduction and was associated with a less immunosuppressive tumor microenvironment and increased PD-L1 expression on tumor cells. Conclusions Our data demonstrate that Id1 expression is involved in the resistance to trametinib and in the synergistic effect of trametinib with anti-PD-1 therapy in KRAS -mutant LUAD tumors. These findings suggest a potential therapeutic approach for immunotherapy-refractory KRAS -mutant lung cancers. Graphical Abstract
Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
Authors: S. Peters, S. Loi, F. André, S. Chandarlapaty, E. Felip, S.P. Finn, P.A. Jänne, K.M. Kerr, E. Munzone, A. Passaro, M. Pérol, E.F. Smit, C. Swanton, G. Viale, R.A. Stahel
Journal: Annals of Oncology (2024)
Multi-granularity learning of explicit geometric constraint and contrast for label-efficient medical image segmentation and differentiable clinical function assessment
Authors: Yanda Meng, Yuchen Zhang, Jianyang Xie, Jinming Duan, Martha Joddrell, Savita Madhusudhan, Tunde Peto, Yitian Zhao, Yalin Zheng
Journal: Medical Image Analysis (2024)

Automated segmentation is a challenging task in medical image analysis that usually requires a large amount of manually labeled data. However, most current supervised learning based algorithms suffer from insufficient manual annotations, posing a significant difficulty for accurate and robust segmentation. In addition, most current semi-supervised methods lack explicit representations of geometric structure and semantic information, restricting segmentation accuracy. In this work, we propose a hybrid framework to learn polygon vertices, region masks, and their boundaries in a weakly/semi-supervised manner that significantly advances geometric and semantic representations. Firstly, we propose multi-granularity learning of explicit geometric structure constraints via polygon vertices (PolyV) and pixel-wise region (PixelR) segmentation masks in a semi-supervised manner. Secondly, we propose eliminating boundary ambiguity by using an explicit contrastive objective to learn a discriminative feature space of boundary contours at the pixel level with limited annotations. Thirdly, we exploit the task-specific clinical domain knowledge to differentiate the clinical function assessment end-to-end. The ground truth of clinical function assessment, on the other hand, can serve as auxiliary weak supervision for PolyV and PixelR learning. We evaluate the proposed framework on two tasks, including optic disc (OD) and cup (OC) segmentation along with vertical cup-to-disc ratio (vCDR) estimation in fundus images; left ventricle (LV) segmentation at end-diastolic and end-systolic frames along with ejection fraction (LVEF) estimation in two-dimensional echocardiography images. Experiments on nine large-scale datasets of the two tasks under different label settings demonstrate our model's superior performance on segmentation and clinical function assessment.
Re: Thomas Powles, Zoe June Assaf, Viraj Degaonkar, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol 2024;85:114–22
Authors: Viria Beccia, Giada Pinterpe, Roberto Iacovelli
Journal: European Urology (2024)
Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 2024;85:105–11
Authors: José D. Cardona Ortegón, Laura A. Campaña Perilla, Laura M. Olarte Bermúdez
Journal: European Urology (2024)
Detecting deception with artificial intelligence: promises and perils
Authors: Kristina Suchotzki, Matthias Gamer
Journal: Trends in Cognitive Sciences (2024)

Rapid advancements in artificial intelligence (AI) have driven interest in its potential application for lie detection. Unfortunately, the current approaches have primarily focused on technical aspects at the expense of a solid methodological and theoretical foundation. We discuss the implications thereof and offer recommendations for the development and regulation of AI-based deception detection.
Re: David Musheyev, Alexander Pan, Stacy Loeb, Abdo E. Kabarriti. How Well Do Artificial Intelligence Chatbots Respond to the Top Search Queries About Urological Malignancies? Eur Urol 2023;85:13–6
Authors: Qi-Fei Deng, Yuan-Yuan Bao, Yuan-Yuan Yang, Chang-Kun Mao
Journal: European Urology (2024)
In vitro models for studying implant-associated biofilms - A review from the perspective of bioengineering 3D microenvironments
Authors: Silvia Cometta, Dietmar W. Hutmacher, Liraz Chai
Journal: Biomaterials (2024)

Biofilm research has grown exponentially over the last decades, arguably due to their contribution to hospital acquired infections when they form on foreign body surfaces such as catheters and implants. Yet, translation of the knowledge acquired in the laboratory to the clinic has been slow and/or often it is not attempted by research teams to walk the talk of what is defined as 'bench to bedside'. We therefore reviewed the biofilm literature to better understand this gap. Our search revealed substantial development with respect to adapting surfaces and media used in models to mimic the clinical settings, however many of the in vitro models were too simplistic, often discounting the composition and properties of the host microenvironment and overlooking the biofilm-implant-host interactions. Failure to capture the physiological growth conditions of biofilms in vivo results in major differences between lab-grown- and clinically-relevant biofilms, particularly with respect to phenotypic profiles, virulence, and antimicrobial resistance, and they essentially impede bench-to-bedside translatability. In this review, we describe the complexity of the biological process at the biofilm-implant-host interfaces, discuss the prerequisite for the development and characterization of biofilm models that better mimic the clinical scenario, and propose an interdisciplinary outlook of how to bioengineer biofilms in vitro by converging tissue engineering concepts and tools.
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study
Authors: Alexander Rimke, Siddhartha Sood, Brian D. Rankin, Abrahim Abduelmula, Jorge R. Georgakopoulos, Khalad Maliyar, Ahmed Bagit, Fernejoy Leung, Lauren A. Stark, Ronald Vender, Jensen Yeung, Vimal H. Prajapati
Journal: Journal of the American Academy of Dermatology (2024)
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol 2024;85:146–53
Authors: None Chao-Yang, Yuan-Yuan Bao, Yuan-Yuan Yang, Chang-Kun Mao
Journal: European Urology (2024)
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61–68
Authors: Ilias Giannakodimos
Journal: European Urology (2024)
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol 2024;85:146–53
Authors: José David Cardona Ortegón, Samuel Serrano, Daniel Romero Cortes
Journal: European Urology (2024)
Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2024;85:217–226
Authors: Elif Hindié, Christophe Champion, Clément Morgat
Journal: European Urology (2024)
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry
Authors: Junfen Zhang, Celeste M. Boesjes, Laura Loman, Esmé Kamphuis, Margreet L.E. Romeijn, Lotte S. Spekhorst, Inge Haeck, Lian F. van der Gang, Coco C. Dekkers, Lisa P. van der Rijst, Albert J. Oosting, Paula van Lumig, Anneke M.T. van Lynden-van Nes, Ron A. Tupker, Annieke Nijssen, Annebeth Flinterman, Klaziena Politiek, Wouter R.H. Touwslager, Wianda A. Christoffers, Shiarra M. Stewart, Marijke Kamsteeg, Marlies de Graaf, Marjolein S. de Bruin-Weller, Marie-Louise A. Schuttelaar
Journal: Journal of the American Academy of Dermatology (2024)

Background Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited. Objective To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients with moderate-to-severe AD over a follow-up period of up to 5 years. Methods Data were extracted from the prospective, multicenter BioDay registry (October 2017 - 2022) of patients with moderate-to-severe AD treated with dupilumab in daily practice. Results In total 1223 patients, 1108 adults and 115 pediatric patients, were included. After ≥1 year of treatment, mean Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Numeric rating scale (NRS)-pruritus ranged between 7.8-8.7, 3.5-4.2, and 2.9-3.1 in adults, respectively, whilst these PROMs ranged between 8.9-10.9, 4.4-6.4, and 3.0-3.7 in pediatric patients, respectively. At follow-up, overall work impairment decreased from 40.1% to 13.3-16.3% in adults. Furthermore, class I obesity and itch-dominant patients generally had less favorable treatment response. Of all patients, 66.8% reported ≥1 adverse event, with conjunctivitis being the most common(33.7%). Limitations The overall percentage of missing values for selected PROMs was 26% in adults and 46% in pediatric patients. Conclusion In addition to favorable safety, dupilumab has demonstrated sustained effectiveness across various PROMs, underscoring the treatment benefits from patients' perspectives.
Corrigendum to “FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosis” [Metabolism 122 (September 2021) 154840]
Authors: Zhaohui Pei, Yandong Liu, Suqin Liu, Wei Jin, Yuanfei Luo, Mingming Sun, Yu Duan, Amir Ajoolabady, James R. Sowers, Yan Fang, Feng Cao, Haixia Xu, Yaguang Bi, Shuyi Wang, Jun Ren
Journal: Metabolism (2024)

The authors regret to report an error in the above-mentioned paper in Fig. 3 as reported. For oil red O staining, density rather than the area of staining was mistakenly reported while a second batch of data was inadvertently left out in the summary analysis (affecting sample size). We have updated the summary graph as shown below (with representations matching mean values), which did not affect the original conclusion. The authors sincerely express their apology for any inconvenience for the readers. FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosisMetabolism - Clinical and ExperimentalVol. 122PreviewFerroptosis is indicated in cardiovascular diseases. Given the prominent role of mitophagy in the governance of ferroptosis and our recent finding for FUN14 domain containing 1 (FUNDC1) in obesity anomalies, this study evaluated the impact of FUNDC1 deficiency in high fat diet (HFD)-induced cardiac anomalies. Full-Text PDF
Dysregulation of CD4<sup>+</sup>and CD8<sup>+</sup>resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis
Authors: Jun Yan He, Yang-Joon Kim, Elvira Mennillo, Iulia Rusu, Jared Bain, Arjun A Rao, Christopher Andersen, Karen Law, Hai Yang, Jessica Tsui, Alan Shen, Brittany Davidson, Divyashree Kushnoor, Yimin Shi, Frances Fan, Alexander Cheung, Li Zhang, Lawrence Fong, Alexis J Combes, Angela O Pisco, Michael G Kattah, David Y Oh
Journal: Journal for ImmunoTherapy of Cancer (2024)

Background Colitis caused by checkpoint inhibitors (CPI) is frequent and is treated with empiric steroids, but CPI colitis mechanisms in steroid-experienced or refractory disease are unclear. Methods Using colon biopsies and blood from predominantly steroid-experienced CPI colitis patients, we performed multiplexed single-cell transcriptomics and proteomics to nominate contributing populations. Results CPI colitis biopsies showed enrichment of CD4 + resident memory (RM) T cells in addition to CD8 + RM and cytotoxic CD8 + T cells. Matching T cell receptor (TCR) clonotypes suggested that both RMs are progenitors that yield cytotoxic effectors. Activated, CD38 + HLA-DR + CD4 + RM and cytotoxic CD8 + T cells were enriched in steroid-experienced and a validation data set of steroid-naïve CPI colitis, underscoring their pathogenic potential across steroid exposure. Distinct from ulcerative colitis, CPI colitis exhibited perturbed stromal metabolism (NAD + , tryptophan) impacting epithelial survival and inflammation. Endothelial cells in CPI colitis after anti-TNF and anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) upregulated the integrin α4β7 ligand molecular vascular addressin cell adhesion molecule 1 (MAdCAM-1), which may preferentially respond to vedolizumab (anti-α4β7). Conclusions These findings nominate CD4 + RM and MAdCAM-1 + endothelial cells for targeting in specific subsets of CPI colitis patients.
Positron emission tomography guided synergistic treatment of melanoma using multifunctional zirconium-hematoporphyrin nanosonosensitizers
Authors: Xiaodan Jiao, Xiaoyang Li, Yan Du, Yiyang Cong, Shuyang Yang, Daiqin Chen, Tao Zhang, Min Feng, Hao Hong
Journal: Journal of Controlled Release (2024)
Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer
Authors: Jing Sun, Jianhui Zhao, Siyun Zhou, Xinxuan Li, Tengfei Li, Lijuan Wang, Shuai Yuan, Dong Chen, Philip J Law, Susanna C Larsson, Susan M Farrington, Richard S Houlston, Malcolm G Dunlop, Evropi Theodoratou, Xue Li
Journal: JNCI Journal of the National Cancer Institute (2024)

We aimed to identify plasma and urinary metabolites related to colorectal cancer (CRC) risk and elucidate their mediator role in the associations between modifiable risk factors and CRC.
Injectable Inflammation‐Responsive Hydrogels for Microenvironmental Regulation of Intervertebral Disc Degeneration
Authors: Lei Liu, Wantao Wang, Lin Huang, Yiwen Xian, Wenzheng Ma, Lei Zhao, Yixi Li, Zhaomin Zheng, Hongmei Liu, Decheng Wu
Journal: Advanced Healthcare Materials (2024)

Chronic local inflammation and excessive cell apoptosis in nucleus pulposus (NP) tissue are the main causes of intervertebral disc degeneration (IDD). Stimuli-responsive hydrogels have great potential in the treatment of IDD by facilitating localized and controlled drug delivery. Herein, an injectable drug-loaded dual stimuli-responsive adhesive hydrogel for microenvironmental regulation of IDD, is developed. The gelatin methacryloyl is functionalized with phenylboronic acid groups to enhance drug loading capacity and enable dual stimuli-responsive behavior, while the incorporation of oxidized hyaluronic acid further improves the adhesive properties. The prepared hydrogel exhibits an enhanced drug loading capacity for diol-containing drugs, pH- and reactive oxygen species (ROS)-responsive behaviors, excellent radical scavenging efficiency, potent antibacterial activity, and favorable biocompatibility. Furthermore, the hydrogel shows a beneficial protective efficacy on NP cells within an in vitro oxidative stress microenvironment. The in vivo results demonstrate the hydrogel's excellent therapeutic effect on treating IDD by maintaining water retention, restoring disc height, and promoting NP regeneration, indicating that this hydrogel holds great potential as a promising therapeutic approach for regulating the microenvironment and alleviating the progression of IDD.
CRISPR/Cas9 nickase mediated signal amplification integrating with the trans-cleavage activity of Cas12a for highly selective and sensitive detection of single base mutations
Authors: Xiao-Wen Fan, Zi-Fan Gao, Dong-Dong Ling, De-Hui Wang, Ying Cui, Hui-Qun Du, Chun-Lin Li, Xing Zhou
Journal: Military Medical Research (2024)
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
Authors: Doris Leithner, Jessica R. Flynn, Sean M. Devlin, Audrey Mauguen, Teng Fei, Shang Zeng, Junting Zheng, Brandon S. Imber, Harper Hubbeling, Marius E. Mayerhoefer, Akshay Bedmutha, Efrat Luttwak, Magdalena Corona, Parastoo B. Dahi, Alejandro Luna de Abia, Ivan Landego, Richard J. Lin, M. Lia Palomba, Michael Scordo, Jae H. Park, Ana Alarcon Tomas, Gilles Salles, Daniel Lafontaine, Laure Michaud, Gunjan L. Shah, Miguel-Angel Perales, Roni Shouval, Heiko Schöder
Journal: Journal of Hematology & Oncology (2024)

Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity are lacking. We examined radiomic features extracted from pre-CAR-T
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
Authors: David R. Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G. Andric, Yi-Long Wu, Charles M. Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis Paz-Ares, Paul A. Bunn, Philip Clingan, Theresa Hayes, Craig Underhill, Wim Demey, Frederic Forget, Marc Lambrechts, Kristiaan Nackaerts, Fabio André Franke, Alan Arrieira Azambuja, Rodrigo Guimaraes, Josiane Mourao Dias, Victor Santos, Bruno Cezar Uchoa Junior, Gustavo Vasconcelos Alves, Claudia Vaz de Melo Sette, Minghong Bi, Jiuwei Cui, Jian Fang, Jianhua Shi, Ke Wang, Zhen Wang, Xinmin Yu, Charles Dayen, Laurent Greillier, Gilles Quere, Alexander Baraniskin, Helge Bischoff, Frank Griesinger, Cornelius Waller, Tibor Csoszi, Gabriella Galffy, Ibolya Laczo, Gyorgy Losonczy, Sandor Tehenes, Angelo Delmonte, Alessandro Follador, Halina Batura-Gabryel, Piotr Centkowski, Iwona Danielewicz, Andrzej Kazarnowicz, Rodryg Ramlau, Alina Simona Muntean, Cristina Marinela Oprean, Michael Schenker, Cristina Tiut, Anghel Adrian Udrea, Andrei Ungureanu, Nina Karaseva, Nikolay Kislov, Elena Poddubskaya, Irina Rozhkova, Ekaterina Solovyeva, Anastasia Zimina, Zoran Andric, Vladimir Kovcin, Marina Petrovic, Zorica Radojevic, Goran Stojanovic, SookHee Hong, Sang-We Kim, Ki Hyeong Lee, Byoung Yong Shim, Miriam Alonso Garcia, Antonio Calles Blanco, Vanesa Gutierrez Calderon, Oscar Jose Juan Vidal, Bartomeu Massuti Sureda, Alejandro Navarro Mendivil, Ramon Palmero Sanchez, Luis Paz-Ares Rodriguez, Ching-Liang Ho, Sheng-Hao Lin, Chien-Ying Liu, Chih-Hsin Yang, Irfan Cicin, Mahmut Gumus, Hakan Harputluoglu, Mustafa Ozguroglu, Erdogan Selcuk Seber, Ahmet Sezer, Hryhoriy Adamchuk, Igor Bondarenko, Yevhen Hotko, Oleh Kobziev, Oleksandr Koshelenko, Andriy Kurochkin, Yuriy Semegen, Ivan Sinielnikov, Tetiana Tarasenko, Dmytro Trukhin, Jennifer Carlisle, Laurie Carr, Arvind Chaudhry, Hongbin Chen, Yuanbin Chen, Afshin Dowlati, Herbert Duvivier, William Edenfield, Maen Hussein, Robert Jotte, Srinivas Jujjavarapu, Brian Lingerfelt, Steven McCune, Nagaprasad Nagajothi, Peter Rubin, Katherine Scilla, David Spigel, Gordan Srkalovic, Amy Weise, Richard Zuniga
Journal: Journal of Clinical Oncology (2024)

The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC).
Effect of air pollution exposure on risk of acute coronary syndromes in Poland: a nationwide population-based study (EP-PARTICLES study)
Authors: Łukasz Kuźma, Emil J. Dąbrowski, Anna Kurasz, Michał Święczkowski, Piotr Jemielita, Mariusz Kowalewski, Wojciech Wańha, Paweł Kralisz, Anna Tomaszuk-Kazberuk, Hanna Bachórzewska-Gajewska, Sławomir Dobrzycki, Gregory Y.H. Lip
Journal: The Lancet Regional Health - Europe (2024)

BackgroundAir pollution (AP) is linked up to 20% of cardiovascular deaths. The aim of this nationwide study was to investigate subpopulations vulnerable to AP for non-ST- (NSTEMI) and ST-elevation myocardial infarction (STEMI) incidence.MethodsWe analysed short- (lags up to seven days) and mid-term (0–30 days moving average) influence of particulate matter (PM2.5), sulphur dioxide (SO2), nitrogen dioxide (NO2) and benzo(a)pyrene (BaP) on hospitalizations due NSTEMI and STEMI in 2011–2020. Data on AP concentrations were derived using GEM-AQ model. Study included residents of five voivodeships in eastern Poland, inhabited by over 8,000,000 individuals.FindingsHigher NO2 and PM2.5 concentrations increased mid-term risk of NSTEMI in patients aged < 65 years by 1.3–5.7%. Increased SO2 and PM2.5 concentration triggered STEMI in the short- (SO2, PM2.5) and mid-term (PM2.5) amongst those aged ≥ 65 years. In the short- and mid-term, women were more susceptible to PM2.5 and BaP influence resulting in increased STEMI incidence. In rural regions, STEMI risk was triggered by SO2, PM2.5 and BaP. Income-based stratification showed disproportions regarding influence of BaP concentrations on NSTEMI incidence based on gross domestic product (up to 1.4%).InterpretationThere are significant disparities in the influence of air pollution depending on the demographic and socio-economic factors. AP exposure is associated with the threat of a higher risks of NSTEMI and STEMI, especially to younger people, women, residents of rural areas and those with lower income.FundingNational Science Center and Medical University of Bialystok, Poland.